EE200300422A - GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks - Google Patents

GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks

Info

Publication number
EE200300422A
EE200300422A EEP200300422A EEP200300422A EE200300422A EE 200300422 A EE200300422 A EE 200300422A EE P200300422 A EEP200300422 A EE P200300422A EE P200300422 A EEP200300422 A EE P200300422A EE 200300422 A EE200300422 A EE 200300422A
Authority
EE
Estonia
Prior art keywords
estrogen
agonists
vitamin
treatment
combination
Prior art date
Application number
EEP200300422A
Other languages
English (en)
Estonian (et)
Inventor
Villalobos Anabella
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300422A publication Critical patent/EE200300422A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200300422A 2001-03-01 2002-02-20 GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks EE200300422A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27256601P 2001-03-01 2001-03-01
PCT/IB2002/000515 WO2002069948A1 (en) 2001-03-01 2002-02-20 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
EE200300422A true EE200300422A (et) 2004-02-16

Family

ID=23040351

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300422A EE200300422A (et) 2001-03-01 2002-02-20 GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks

Country Status (33)

Country Link
US (2) US20020193360A1 (is)
EP (1) EP1363606A1 (is)
JP (1) JP2004527500A (is)
KR (1) KR20030076717A (is)
CN (1) CN1494422A (is)
AP (1) AP2002002465A0 (is)
AR (1) AR033425A1 (is)
BG (1) BG108131A (is)
BR (1) BR0207802A (is)
CA (1) CA2439581A1 (is)
CR (1) CR7059A (is)
CZ (1) CZ20032338A3 (is)
DO (1) DOP2002000345A (is)
EA (1) EA200300854A1 (is)
EC (1) ECSP034759A (is)
EE (1) EE200300422A (is)
GT (1) GT200200039A (is)
HU (1) HUP0303448A3 (is)
IL (1) IL157465A0 (is)
IS (1) IS6905A (is)
MA (1) MA26999A1 (is)
MX (1) MXPA03007834A (is)
NO (1) NO20033821L (is)
NZ (1) NZ527397A (is)
OA (1) OA12554A (is)
PA (1) PA8540701A1 (is)
PE (1) PE20020927A1 (is)
PL (1) PL364081A1 (is)
SK (1) SK10752003A3 (is)
TN (1) TNSN02018A1 (is)
UY (1) UY27188A1 (is)
WO (1) WO2002069948A1 (is)
ZA (1) ZA200306193B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US8030300B2 (en) 2003-06-10 2011-10-04 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
EP1924712B1 (en) * 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007139818A2 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
AU2013202426B2 (en) * 2006-10-16 2015-08-06 Bionomics Limited Novel anxiolytic compounds
EP2540722B1 (en) * 2006-10-16 2016-06-08 Bionomics Limited Novel anxiolytic compounds
CA2873179A1 (en) 2007-02-09 2008-08-21 Blanchette Rockefeller Neurosciences Institute Use of bryostatins and neristatins in the treatment of cognitive impairment due to head trauma
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) * 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
RU2012102052A (ru) * 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
NO3034079T3 (is) 2010-11-15 2018-06-09
JP2014510065A (ja) 2011-03-02 2014-04-24 バイオノミックス リミテッド 治療薬としての新規な小分子
US20140051701A1 (en) * 2011-03-02 2014-02-20 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US9133188B2 (en) 2011-05-12 2015-09-15 Bionomics Limited Methods for preparing naphthyridines
NZ722077A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2016279052A1 (en) 2015-06-19 2018-02-15 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN116008442B (zh) * 2023-03-27 2023-06-30 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) * 2023-04-10 2023-07-07 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010023313A (ko) * 1997-08-25 2001-03-26 해피 페너 ; 해리 에이치. 페너 2세 Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands

Also Published As

Publication number Publication date
AR033425A1 (es) 2003-12-17
UY27188A1 (es) 2002-10-31
BG108131A (en) 2004-09-30
KR20030076717A (ko) 2003-09-26
DOP2002000345A (es) 2002-12-15
SK10752003A3 (sk) 2004-08-03
US20040082555A1 (en) 2004-04-29
US20020193360A1 (en) 2002-12-19
CA2439581A1 (en) 2002-09-12
PL364081A1 (en) 2004-12-13
ZA200306193B (en) 2004-08-11
MXPA03007834A (es) 2003-12-08
AP2002002465A0 (en) 2002-06-30
GT200200039A (es) 2002-11-21
IL157465A0 (en) 2004-03-28
IS6905A (is) 2003-08-07
OA12554A (en) 2006-06-07
MA26999A1 (fr) 2004-12-20
CN1494422A (zh) 2004-05-05
NO20033821L (no) 2003-09-10
HUP0303448A3 (en) 2005-05-30
JP2004527500A (ja) 2004-09-09
NZ527397A (en) 2005-05-27
TNSN02018A1 (fr) 2005-12-23
EA200300854A1 (ru) 2004-02-26
WO2002069948A1 (en) 2002-09-12
ECSP034759A (es) 2003-10-28
CR7059A (es) 2004-03-10
HUP0303448A2 (hu) 2004-01-28
NO20033821D0 (no) 2003-08-28
EP1363606A1 (en) 2003-11-26
BR0207802A (pt) 2004-03-09
CZ20032338A3 (cs) 2004-08-18
PE20020927A1 (es) 2002-10-30
PA8540701A1 (es) 2002-09-30

Similar Documents

Publication Publication Date Title
EE200300422A (et) GABAA pöördagonistide kasutamine kombinatsioonis nikotiiniretseptori osaliste agonistide, östrogeeni, selektiivsete östrogeeni modulaatorite või vitamiin E-ga kognitiivsete häirete raviks
DK1110949T3 (da) EP4-receptorselektive agonister, som er anvendelige ved behandling af osteoporose
BR0117199B1 (pt) dispositivo para realização de osteosìntese.
DK1144388T3 (da) Acyl-derivater, som behandler VLA-4-relaterede lidelser
DE60219271D1 (de) Drucksystem, Druckgerät, Druckverfahren und Druckprogramm
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
DE60200528D1 (de) Vorrichtung mit abnehmbarer Gleitzentralkonsole
DK1497293T3 (da) (1,4)Diazepino(6,7,1-ij)quinolinderivater som antipsykotiske og antiobesitetsmidler
BR0105828B1 (pt) dispositivo para locomoÇço de deficientes fÍsicos.
ATE384697T1 (de) 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
BR0312460B1 (pt) suporte sàlido, processo de preparaÇço, e, uso do mesmo.
ATE472545T1 (de) 8-ä4-ä3-(5-fluoro-1h-indol-3-yl)propylü -1- piperazinylü -2-methyl-2h-1, 4-benzoxazin-3(4h)- on methanesulfonat mit hoher affinität für den dopamin d2 rezeptor und den serotonin reuptake site
BRPI0613443A2 (pt) método para tratamento de superfície de um objeto, rolo de fio, e, uso do método"
BRPI0310056A2 (pt) método de transpiração térmica, recipiente de transpiração térmica e aparelho de transpiração térmica utilizados para o mesmo
ITMI20041825A1 (it) Agonisti dei ricettori attivanti la proliferazione dei perossisomi, utili nella prevenzione o nel trattamento della gastrite
ES1049094Y (es) Dispositivo para la formacion de chaflanes en encofrados.
ITRM20040642A1 (it) Procedimento e dispositivo per l'autenticazione delle comunicazioni.
ES1048055Y (es) Dispositivo para la aplicacion de tintes capilares.
ES1052375Y (es) Dispositivo de baño para pacientes.
ES1049121Y (es) Dispositivo de sustentacion perfeccionado para cortinas y similares.
ES1050258Y (es) Tapon con caperuza, perfeccionado
BR8101479Y1 (pt) aparelho para testes de carbonatação em latas.
BR8102921Y1 (pt) disposição introduzida em clipe articulado graduado para óculos de segurança.
ITPD20030313A1 (it) Apparechiatura per il controllo della somministrazione di test di tipo cognitivo, psicofisico e simili